Hancock Whitney’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Hancock Whitney’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-12,444	Closed	-$124K	–	835
2020 Q2	$124K	Buy	+12,444	New	+$119K	﹤0.01%	741
2019 Q1	–	Sell	-30,771	Closed	-$386K	–	882
2018 Q4	$386K	Sell	30,771 -7,669	-20%	-$106K	0.01%	660
2018 Q3	$570K	Sell	38,440 -3,970	-9%	-$62.5K	0.02%	618
2018 Q2	$714K	Buy	+42,410	New	+$824K	0.03%	394

Other funds holding CNCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

L1 Capital Melbourne VIC 3000, Australia $2.55B AUM 80.12% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hancock Whitney's CNCE Position: Q3 2020 in Review

Hancock Whitney sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2020, closing a stake of 12,444 shares — an estimated $124K sold.

Hancock Whitney first reported a position in CNCE in Q2 2018 and held it in 4 quarters. The position peaked at $714K in Q2 2018. 92 funds tracked by Wall St. Rank hold CNCE as of Q3 2020.

Hancock Whitney reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
Hancock Whitney sold 12,444 Concert Pharmaceuticals, Inc. shares in Q3 2020, an estimated $124K.
Hancock Whitney first reported a position in Concert Pharmaceuticals, Inc. in Q2 2018 and held it in 4 quarters.
Hancock Whitney's Concert Pharmaceuticals, Inc. position peaked at $714K in Q2 2018.
92 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2020.

Based on Hancock Whitney's 13F filing for Q3 2020, filed 5 Nov 2020.